Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Imaging outcome measures for progressive multiple sclerosis trials.

Moccia M, de Stefano N, Barkhof F.

Mult Scler. 2017 Oct;23(12):1614-1626. doi: 10.1177/1352458517729456.

2.

An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a.

Yamazaki Y, Suzuki A, Hirayanagi K, Tsukagoshi Y, Uehara R, Horiguchi K, Ohyama T, Tomaru T, Horiguchi N, Nobusawa S, Ikota H, Sato K, Kakizaki S, Kusano M, Ikeda Y, Yokoo H, Yamada M.

Intern Med. 2017;56(14):1897-1901. doi: 10.2169/internalmedicine.56.7980. Epub 2017 Jul 15.

3.

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle.

Abdelhak A, Weber MS, Tumani H.

Front Neurol. 2017 May 31;8:234. doi: 10.3389/fneur.2017.00234. eCollection 2017. Review.

4.

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.

Dupuy SL, Khalid F, Healy BC, Bakshi S, Neema M, Tauhid S, Bakshi R.

BMC Med Imaging. 2016 Oct 5;16(1):56.

5.

Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis.

Yiannakas MC, Mustafa AM, De Leener B, Kearney H, Tur C, Altmann DR, De Angelis F, Plantone D, Ciccarelli O, Miller DH, Cohen-Adad J, Gandini Wheeler-Kingshott CA.

Neuroimage Clin. 2015 Nov 10;10:71-7. doi: 10.1016/j.nicl.2015.11.001. eCollection 2016.

6.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Torkildsen Ø, Myhr KM, Bø L.

Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883. Review.

7.

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.

Ziemssen T, Rauer S, Stadelmann C, Henze T, Koehler J, Penner IK, Lang M, Poehlau D, Baier-Ebert M, Schieb H, Meuth S.

PLoS One. 2015 Sep 22;10(9):e0138243. doi: 10.1371/journal.pone.0138243. eCollection 2015. Review.

8.

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.

Wiendl H, Meuth SG.

Drugs. 2015 Jun;75(9):947-77. doi: 10.1007/s40265-015-0411-0. Review.

9.

The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.

Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S.

Prog Neurobiol. 2015 Apr;127-128:1-22. doi: 10.1016/j.pneurobio.2015.02.003. Epub 2015 Mar 21. Review.

10.

Relapses and disability accumulation in progressive multiple sclerosis.

Paz Soldán MM, Novotna M, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Weinshenker BG, Rodriguez M, Kantarci OH.

Neurology. 2015 Jan 6;84(1):81-8. doi: 10.1212/WNL.0000000000001094. Epub 2014 Nov 14.

11.

Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis.

de la Pena I, Pabon M, Acosta S, Sanberg PR, Tajiri N, Kaneko Y, Borlongan CV.

Cell Med. 2014 Apr 10;6(3):123-127.

12.

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.

Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, Akbari Sari A.

Daru. 2013 Jun 22;21(1):50. doi: 10.1186/2008-2231-21-50.

13.

Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M.

Dig Dis Sci. 2013 Jun;58(6):1766-75. doi: 10.1007/s10620-012-2553-1. Epub 2013 Feb 2.

14.

Interferon beta and glatiramer acetate therapy.

McGraw CA, Lublin FD.

Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4. Review.

15.

Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.

Fitzner D, Simons M.

Curr Neuropharmacol. 2010 Sep;8(3):305-15. doi: 10.2174/157015910792246218.

16.

Ring and nodular multiple sclerosis lesions: a retrospective natural history study.

Davis M, Auh S, Riva M, Richert ND, Frank JA, McFarland HF, Bagnato F.

Neurology. 2010 Mar 9;74(10):851-6. doi: 10.1212/WNL.0b013e3181d31df5.

17.

Early stage and long term treatment of multiple sclerosis with interferon-beta.

Applebee A, Panitch H.

Biologics. 2009;3:257-71. Epub 2009 Jul 13.

18.

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

Gaindh D, Jeffries N, Ohayon J, Richert ND, Pellicano C, Frank JA, McFarland H, Bagnato F.

Expert Opin Biol Ther. 2008 Dec;8(12):1823-9. doi: 10.1517/14712590802510629 .

19.

Assessing walking speed in clinical research: a systematic review.

Graham JE, Ostir GV, Fisher SR, Ottenbacher KJ.

J Eval Clin Pract. 2008 Aug;14(4):552-62. doi: 10.1111/j.1365-2753.2007.00917.x. Epub 2008 May 2. Review.

20.

Pediatric multiple sclerosis.

Chabas D, Green AJ, Waubant E.

NeuroRx. 2006 Apr;3(2):264-75. Review.

Supplemental Content

Support Center